Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
41°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
40.90
-0.32 (-0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
Next >
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
April 22, 2024
Via
Benzinga
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
April 15, 2024
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data.
Via
Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
April 05, 2024
Via
Benzinga
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
March 18, 2024
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q4 Earnings
February 15, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Preview: Ultragenyx Pharmaceutical's Earnings
February 14, 2024
Via
Benzinga
4 Analysts Have This To Say About Ultragenyx Pharmaceutical
January 19, 2024
Via
Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
Expert Ratings for Ultragenyx Pharmaceutical
December 08, 2023
Via
Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
November 03, 2023
Via
Benzinga
Earnings Outlook For Ultragenyx Pharmaceutical
November 01, 2023
Via
Benzinga
AT&T, Union Pacific, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
October 19, 2023
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 30 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
October 10, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
August 01, 2023
Via
Benzinga
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 19, 2023
Gainers
Via
Benzinga
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 18, 2023
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
June 06, 2023
Via
Benzinga
Stocks Fall As Bond Yields Hit Multi-Year Highs
October 18, 2023
The major indexes are firmly lower this afternoon, with both the Dow Jones Industrial Average and Nasdaq Composite down triple digits as bond yields rise.
Via
Talk Markets
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 17, 2023
Via
Benzinga
Why Is Mereo BioPharma Stock Trading Higher Today?
October 16, 2023
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
June 06, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.